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Background: Control of classical swine fever (CSF) by vaccination ideally requires that field strain infection can be
detected irrespective of the vaccination status of the herd. To inform on the usefulness of molecular tests compatible
with genetic Differentiation of Infected from Vaccinated Animals (DIVA) principles when using live-attenuated vaccines,
tonsil homogenates from a vaccination-challenge experiment were analyzed using a differential real-time qRT-PCR for
the C-strain vaccine or real-time qRT-PCR assays developed to specifically detect the challenge strains used.
Results: In animals with high or moderate levels of blood viraemia, which were not, or not fully, protected by
vaccination, challenge virus RNA was readily detected in tonsil homogenates. In three out of the seven vaccinated
animals that had high or moderate viraemia, the vaccine strain RNA also could be detected but at lower levels. Lower
but varying levels of challenge and/or vaccine virus RNA were detected in tonsil homogenate samples from animals
with no or low-level viraemia, and in groups solely consisting of such animals, no transmission of infection to na?ve
in-contact animals occurred. In one group of animals that were vaccinated 3 days prior to challenge, viraemia levels
varied from high to absent and transmission of challenge virus to na?ve in-contact animals occurred. The DIVA assay
revealed challenge virus in all tonsil homogenates from this group, even in those animals that did not have viraemia
and were protected from clinical disease by vaccination. Such animals, particularly in a low biosecurity/informal farm
setting, could constitute a risk for disease control in the field.
Conclusions: Genetic DIVA testing is useful for detecting the presence of field virus infection especially in non-viraemic
animals without overt clinical signs but which are incompletely protected by vaccination. Such tests could particularly
be useful to inform decisions prior to and during cessation of a control strategy that employs vaccination.
Keywords: Classical swine fever virus, DIVA PCR test, Infection, Vaccination, C-strainBackground
Classical swine fever virus (CSFV), a Pestivirus in the fam-
ily Flaviviridae, causes a severe, often fatal, hemorrhagic
disease of pigs and remains a serious threat to pig welfare
and pork production worldwide [1]. The live, attenuated
Riemser C-strain is a safe and effective vaccine for CSFV
[2,3] that provides robust immunity to infection and pre-
vents virus transmission within 5 days of vaccination [4].
C-strain vaccines are widely used in regions where clas-
sical swine fever (CSF) remains endemic, such as Asia and
Central-South America [2]. Within the EU, use of C-strain
vaccination in domestic pig herds is only authorized
during emergency situations as the vaccine does not allow
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licence.htm.However, deployment of C-strain vaccine in oral baits is
permitted to control CSF in wild boar [5,6] and has been
used to assist in the eradication of CSF from low biosecur-
ity/informal swine holdings in Romania [7]. Whilst devel-
opment of an efficacious DIVA vaccine is progressing
[8-10] and the corresponding real-time RT-PCR [11] and
serological DIVA tests have been developed [12], until
such time as a DIVA capability is widely available, pre-
existing C-strain vaccines remain important tools for
CSF control.
CSFV vaccine viral RNA is not always readily detected
post vaccination. Blood and tissue homogenate samples
obtained following intramuscular vaccination may con-
tain detectable levels of vaccine viral RNA when moni-
tored by CSFV-specific, real-time RT-PCR assays. Commonly,
post-vaccination positive results in blood are only ob-
tained following inoculation with high doses of vaccineral. This is an open-access article distributed under the terms of the free Open
ed use, distribution and reproduction in any medium, provided the original
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of 16 days post-vaccination (dpv) [8,13,14]. Low levels
of vaccine RNA are detectable in tonsil or oropharyn-
geal fluid samples for extended periods of time [14,15],
particularly in tonsil samples, with 98dpv being the lon-
gest duration reported [8]. These findings indicate that
vaccination elicits a transient low-level viraemia which
is hard to detect and does not result in high viral loads
in vivo. There is no evidence that vaccinated pigs shed
or horizontally transmit the C-strain vaccine ([14,16] and
data not shown).
Leifer and colleagues developed a real-time RT-PCR
assay to specifically detect the C-strain for use as a genetic
DIVA test in circumstances where this vaccine might be
used [17]. This assay was subsequently modified to
accommodate nucleotide variations found in different
C-strain vaccine batches and now also detects all geno-
type 1.1 CSFV strains, including the C-strain [18]. This
modified genotype 1.1 assay has been successfully used, in
combination with a real-time RT-PCR assay that detects
all known CSFV strains, to distinguish C-strain vaccine
from the circulating field strains which do not belong to
genotype 1. For example, following a campaign to vaccin-
ate wild boar in Germany using oral baits, C-strain vac-
cine could be distinguished from the genotype 2.3 field
virus in CSFV RNA positive samples obtained from
hunted wild boar [19]. Another differential assay has been
developed that can distinguish the genetically similar
Riemser C-strain, HCLV and LPC vaccine strains from
most field strain genotypes except some of the genotype 3
strains [20,21]. Other differential real-time RT-PCR tests
have been developed to specifically detect diverse CSFV
vaccine strains [22-24]. However, because of sequence
variation, they are not specific for the Riemser C-strain
vaccine licensed for use in the EU.
Little is known regarding the likelihood of detecting
vaccine or field CSFV strains in vaccinated and then
challenged domestic pigs. We therefore assessed wild-
type and vaccine CSFV RNA levels in pigs that were vac-
cinated with the Riemser C-strain and then challenged
intranasally with one of two moderately virulent field
strains [4], either the genotype 2.1 UK2000/7.1 strain
[25], or the genotype 3.3 Thai CBR/93 strain [26]. Chal-
lenge strains with distinct genotypes to the vaccine
strain were chosen to enable assessment of vaccine effi-
cacy. The genetic diversity of CSFV strains has impeded
efforts to develop a differential assay that will specifically
detect all virulent field strains but exclude all vaccine
strains. In this study, we therefore developed differential
real-time, qRT-PCR assays that were specifically de-
signed to detect the individual challenge strains. The
RNA levels of the vaccine or challenge viruses in tonsil
homogenates from pigs with varied status of protection
or disease were then assessed.Results
In order to assess the specificity of each differential
PCR design, a template mixture containing 104 copies of
C-strain, CBR/93 and UK2000/7.1 RNA was analyzed
using the differential genotype 1.1 real-time RT-PCR
developed for the Riemser C-strain [17,18] together
with quantification standards or differential real-time
qRT-PCR assays developed specifically to detect the chal-
lenge strains. The specificity of the genotype 1.1 assay
depends on a single nucleotide at the 3 ? end of each
primer, and, as expected, only produced an amplicon
from the C-strain template and not from the other viral
strains (Figure 1A). Additional amplicons were consist-
ently produced in lower concentrations when using this
primer pair, possibly owing to the requirement for a re-
dundant primer. In contrast, primers used in the assays
for detection of challenge strains CBR/93 or UK2000/7.1
(HE5 and HE4.1/4.2) amplified all strains equivalently,
therefore the discrimination by these assays depended
entirely on the specificity of the cognate locked nucleic
acid (LNA) probe. Each real-time qRT-PCR assay was
specific for the intended target strain and did not de-
tect the non-cognate strain (Figure 1B to D). The sensi-
tivity of the differential assays for the challenge strains
were evaluated using a standard curve prepared from a
serial 10-fold dilution of viral RNA from the correspond-
ing viral strain that had been quantified using a pan-CSFV
PCR [27]. Although having a less sensitive detection limit
than the 10 copies/assay reported for the genotype
1.1 assay [17], the challenge strain differential assays
allowed reliable quantification of template RNA down
to 102 copies/assay (Table 1).
Vaccination with the C-strain produces very low or un-
detectable levels of viraemia in blood ([8,13,14] and un-
published observations). To identify the most appropriate
tissue sample for detection of C-strain, homogenates of
tonsil, spleen and lateral retropharyngeal, ileocecal, man-
dibular and pre-scapular lymph nodes from animals eu-
thanized between 11 and 33 days post-challenge were
assessed. Tonsil samples allowed most consistent detec-
tion of C-strain RNA in vaccinated animals (data not
shown) and this was in agreement with previous studies
[8,14,15,28]. The amounts of total CSFV, C-strain, CBR/
93 and UK2000/7.1 RNA were determined in tonsil tissue
homogenates prepared from animals that had been vacci-
nated 5, 3 or 1 days prior to challenge with either the
CBR/93 or UK2000/7.1 (Table 2). Control homogenates
were prepared from mock-vaccinated, infected animals
[4]. As expected, the total viral load increased as the level
of protection afforded by vaccination decreased. When
high or moderate blood viraemia occurred, this correlated
with a high level of total CSFV in tonsil which was mainly
comprised of challenge virus. The animals in this category
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Figure 1 Specificity of differential PCR assays for detection of C-strain (C-str), CBR/93 and UK2000/7.1 (UK) RNA templates. Panel A: Whereas
the genotype 1 specific real-time RT-PCR assay previously described [17,18] only produced a C-strain vaccine amplicon (Lane 1? 3), the primer mix HE5
and HE4.1/4.2 amplified the C-strain (C-str), CBR/93 and UK2000/7.1 (UK) strains equally (Lanes 4? 9). Panels B to D: Differential real-time RT-PCR analysis
of a mixture of 104 copies of the three viral RNA templates revealed that the C-strain (B), CBR/93 (C) or UK2000/7.1 (D) assays were specific for their
respective templates.
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mals would be expected to be identified as infected. Herds
harboring such animals would also be correctly designated
CSFV positive and indeed, na?ve animals co-housed with
these experimental groups also developed CSF.
The situation was more complex in Groups B, C and F
(Table 2) where the animals developed low or no vir-
aemia. These animals were protected by vaccination,
appeared clinically healthy and did not transmit CSFV
to na?ve animals placed in contact. In one viraemic ani-
mal (C4), a mixture of challenge and vaccine strain
could be detected in tonsil. However, in other animals,
the source of viraemia was probably the C-strain (CBR/
93 challenged animals B.1, C.2, and C.5 and UK2000/7.1
challenged animals F.1 and F.6) or could not be distin-
guished (CBR93 challenged animal C.1). In the absence
of blood viraemia, if CSFV RNA was detected in tonsilTable 1 Detection limits of the challenge strain-specific
probes assessed using a dilution series of standard




5 ? 10 5 27.3 30.7
5 ? 10 4 31.3 34.2
5 ? 10 3 34.9 37.6
5 ? 10 2 38.5 42.0
5 ? 10 1 None Nonesamples, this was due to C-strain vaccine and challenge
virus was not detectable in tonsil tissue.
The results obtained for Group G, challenged with the
UK2000/7.1 strain three days post-vaccination, were
varied. This group included one animal (G.1) that devel-
oped clinical signs unrelated to CSFV infection and sub-
sequent elevated CSFV viraemia. All other challenged
animals in the group remained clinically healthy, despite
low levels of viraemia in some (G2, G3 and G5) but
na?ve in-contact animals became infected. Interestingly,
two animals (G.4 and G.6) did not develop viraemia and
low levels of challenge virus could be detected in tonsil.
It is possible that virus shed by the viraemic animal G.1
was taken up by animals G.4 and G.6 and was retained
in tonsil but vaccine-mediated protection limited
infection.
Discussion
In this study, the C-strain vaccine, CBR/93 and UK2000/
7.1 CSFV strains could clearly be individually distin-
guished in clinical samples using a differential qRT-PCR
approach. In high or moderately viraemic animals, the
challenge strain contributed the majority of total viral
RNA in tonsil extracts. In the field, such infected animals
would likely have clinical signs and would be correctly
identified as CSFV positive by routine CSFV molecular
tests that do not discriminate vaccine from challenge
virus. Consequently, a herd including such animals would
be identified as infected. In animals with low-level vir-
aemia, tonsil extracts contained detectable levels of either
vaccine and/or challenge virus. In a vaccination strategy
Table 2 Detection of CSFV in tonsil extracts













Tonsil RNA levels (log10 copies/ng) Clinical
outcome
End day
(dpi)CBR/93 C-strain Total CSFV UK2000/7.1 C-strain Total CSFV
Mock vaccination* Mock vaccination*
A.1 High 7.10 0 8.62 Euthanized 17 E.1 High 9.39 0 9.43 Euthanized 17
A.2 Moderate 4.99 0 8.21 Euthanized 21 E.2 Moderate 8.50 0 8.87 Euthanized 15
A.3 High 6.23 0 8.18 Euthanized 21 E.3 High 8.35 0 8.56 Euthanized 15
A.4 Moderate 6.02 0 8.06 Euthanized 17 E.4 High 7.98 0 8.48 Euthanized 17
Vaccination -5 dpi Vaccination -5 dpi
B.1 Low < assay 4.61 5.19 Healthy 25 F.1 Low 0 3.64 4.38 Healthy 29
B.2 ⊗ 0 2.76 3.62 Healthy 25 F.2 ⊗ 0 3.23 3.61 Healthy 29
B.3 ⊗ 0 1.61 3.76 Healthy 30 F.3 ⊗ 0 2.93 3.42 Healthy 30
B.4 ⊗ 0 1.92 3.25 Healthy 30 F.4 ⊗ 0 2.19 3.41 Healthy 30
B.5 ⊗ 0 1.66 2.96 Healthy 30 F.5 ⊗ 0 1.81 0.87 Healthy 29
B.6 ⊗ 0 2.21 2.87 Healthy 25 F.6 Low 0 1.83 0.11 Healthy 30
Vaccination -3 dpi Vaccination -3 dpi*
C.1 Low < assay 0 4.17 Healthy 33 G.1 High 7.79 2.75 8.33 unrelated inf. 22
C.2 Low 0 1.65 3.74 Healthy 32 G.2 Low 8.01 0 8.23 Healthy 28
C.3 ⊗ 0 1.24 3.45 Healthy 33 G.3 Low 2.75 4.29 5.13 Healthy 28
C.4 Low 0.5 1.45 3.43 Healthy 32 G.4 ⊗ 1.06 3.80 4.78 Healthy 24
C.5 Low < assay 1.35 3.16 Healthy 32 G.5 Low 2.63 1.74 4.08 Healthy 24
C.6 ⊗ 0 0 2.51 Healthy 33 G.6 ⊗ 1.98 1.12 3.35 Healthy 24
Vaccination -1 dpi* Vaccination -1 dpi*
D.1 High 7.28 0 8.69 Euthanized 19 H.1 High 7.51 0 8.69 Euthanized 19
D.2 Moderate 7.75 4.26 8.68 Euthanized 12 H.2 High 7.98 0 8.21 Euthanized 12
D.3 Moderate 3.03 < assay 5.62 Healthy 23 H.3 Moderate 7.99 4.16 8.16 Euthanized 11
D.4 Low 2.28 1.02 5.10 unrelated inf. 19 H.4 Low 4.65 0 5.43 Healthy 23
D.5 Low 0.76 2.53 4.15 Healthy 23 H.5 Low 2.59 1.00 4.41 Healthy 23
D.6 Low < assay < assay 2.77 Healthy 23 H.6 Low 2.67 1.58 4.16 Healthy 23
*Na?ve animals co-housed together with these groups became CSFV infected.
Pigs were mock-vaccinated or vaccinated at 1, 3, or 5 days before inoculation with (A) the CBR/93 or (B) the UK2000/7.1 field strains. Blood viraemia is recorded as not detectable (⊗), low, moderate or high. The amount of
CBR/93, UK20007.1 or C-strain vaccine RNA determined using differential real-time qRT-PCR or of total CSFV RNA quantified using a routine real-time qRT-PCR assay is shown as log10 viral RNA copy per ng 18S RNA. Bold type
indicates high copy number. Samples with high Ct values below the quantifiable limit of an assay (< assay) or no Ct value (0) are indicated. The clinical outcome shows those animals that reached the humane endpoint and
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ical criteria and testing with non-discriminatory tests
could either miss a field infection or lead to incorrect dec-
larations of disease in a herd.
This study has shown that the situation is even more
complex in those animals which do not develop viraemia
but have variable protection status and may be infected
with field virus. In the non-viraemic animals that had
been challenged with the CBR/93 strain 3 days after vac-
cination, the vaccine strain could be detected in tonsil
samples from one animal (Table 2, C.3) but the identity
of the strain could not be determined in the second ani-
mal (C.6). Although the four other challenged animals
exhibited a transient viraemia, a very low level of chal-
lenge virus was only found in one animal and in-contact
animals remained healthy, indicating there was no trans-
mission of challenge virus [4]. A converse outcome was
observed when animals were challenged with the UK2000/
7.1 strain at 3 days post-vaccination (Group G). The pres-
ence of one animal with a high level of viraemia in this
group (G.1), which most likely resulted in infection of in-
contact animals [4], did not allow clear conclusions to be
made. However, it is noteworthy that the challenge strain
RNA could be detected in tonsil samples from two non-
viraemic, challenged animals that were apparently protected
by vaccination (G.4 and G.6). Other studies have shown
that detection of challenge virus does not always indicate
infection. Presence of wild-type virus RNA in clinically
healthy, vaccinated animals has been reported [15,29] and
retention of challenge virus RNA in oropharyngeal fluid of
a vaccinated animal was reported not to cause infection of
na?ve in-contact animals [15] possibly as a result of virus
being sequestered in a non-infectious state within immune
complexes or phagocytic cells. The likelihood of infectious
virus being transmitted from such non-viraemic, vaccinated,
animals to initiate infection remains unclear, but could
compromise a vaccination campaign for CSFV eradication,
particularly in low biosecurity farming sectors.
These risks can be better understood by applying DIVA
assays for monitoring a vaccination strategy. Ideally, a
DIVA assay would detect field strain infection, irrespective
of whether animals had been vaccinated. Field-strain spe-
cific RT-PCR assays have been developed [22,23], however
they rely upon pre-existing sequence information about
circulating field strains and are susceptible to viral genome
changes as such assays often rely on one or two nucleo-
tide differences between the field strain and vaccine.
An alternative approach is to test samples for the pres-
ence of all CSFV strains and then apply a vaccine-specific
test [17,18,20]. This strategy assumes that an animal is not
infected if vaccine-specific RNA is detected in tonsil tis-
sue. Whilst this may be an acceptable risk in a wild boar
vaccination campaign, a potential failure to detect field
virus in the domestic pig sector would be of concern.This issue can be overcome by use of a DIVA vaccine,
such as the candidate CP7_E2alf vaccine, that has the po-
tential for allowing serological and genetic DIVA assays to
be applied [8-10].
Conclusions
Our DIVA study has shown that non-immune animals
(mock-vaccinated or vaccinated 1 day prior to challenge)
which develop a high or moderate level of blood viraemia,
harbor challenge virus that can clearly be detected in ton-
sil tissue. Completely protected animals (vaccinated 5 days
or more before challenge) develop low, if any viraemia.
Only vaccine virus was detected in the tonsil of the pro-
tected animals, therefore applying a DIVA strategy based
on the detection of total CSFV to exclude infection based
on the detection of vaccine would represent little risk of
missing infection in an individual animal. However, for an-
imals that are not completely protected, for example due
to poor pre-existing health status or exposure to field
virus before or shortly after vaccination, there is a greater
risk of individual animals harboring a mixture of field and
vaccine viruses. The potential consequence of this risk to
the particular vaccination and testing strategy must there-
fore be considered. Vaccinated domestic pigs that also
carry infectious virus, while probably not common, are
difficult to identify within a herd. Such animals could po-
tentially serve as a reservoir of infectious virus and initiate
re-emergence of disease after the end of a vaccination
campaign. This risk could be mitigated by imposing move-
ment restrictions for two weeks after vaccination and
monitoring CSFV in unvaccinated sentinel animals within
a herd. These control efforts could be supported by apply-
ing genetic DIVA tests to assess herds or slaughter ani-
mals during and before ending a vaccination campaign.
Methods
Tissue samples were obtained at necroscopy during a pre-
viously described study [4] and stored at −80?C. Briefly,
in this study conducted following AHVLA Ethics com-
mittee approval and in accordance with the UK Animals
(Scientific Procedures) Act 1986, ten-week old domes-
tic pigs, were vaccinated by intramuscular injection
of 100PD50 of the Riemser C-strain vaccine (Riemser
Arzneimittel) according to the manufacturer ? s protocol at
intervals of 1, 3, or 5 days prior to intranasal inoculation
with either the UK2000/7.1 [25] or CBR/93 field strain
[26]. Control pigs were mock vaccinated prior to inocula-
tion. Pigs were euthanized on completion of the study at
30? 33 days post inoculation (dpi) or on the dpi indicated
in Table 2 as determined by the score assigned to their
clinical signs [30]. Blood viraemia results were reported
previously [4] and are indicated in Table 2 as positive if
total CSFV viral RNA could be detected in blood
from an animal on two or more consecutive sampling
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number/μl blood did not exceed 3.99, moderate if be-
tween 4.00 and 5.99 and high if in excess of 6.00.
Tissue samples between approximately 0.2 to 0.5 g were
homogenized in 1.5 ml PBS using an Omni-TH Tissue
Homogenizer (Omni International). Homogenates were
extracted using the QIAamp viral RNA mini kit (Qiagen).
The total CSFV genomic RNA copy number was deter-
mined by real-time RT-PCR [27,31] together with quanti-
fication standards. The C-strain was detected using a
differential real-time qRT-PCR assay [17] with a modified
5? primer [18] as the C-strain batch used to vaccinate pigs
contained a mixed population of virus genotypes with a
purine base in the 1649 position corresponding to the 3?
terminal nucleotide of the 5? primer used in this discrim-
inatory assay. The PCR strategy to differentiate the
UK2000/7.1 and Thai CBR/93 strains from the vaccine
virus was designed to equally amplify a 233 nucleotide re-
gion within the Npro gene using the 5? primer HE5
(TGGGAGTGGAGGAACCG) and a 2:1 molar ratio mix-
ture of the 3? primers HE4.1/4.2 (GCCCATGTAGTCCTG
ATAGWAGAC) and (GCCCATGTAGTCCTGATAAA
AGAC). Locked nucleic acid (LNA) probes were used to
discriminate the wild-type challenge strains from the
vaccine. The probes used to detect the two challenge
strains were UK2000/7.1: Fam-CCACT(+A)AC(+T)GG
(+T)CCTAG(+G)TG(+G)TTT-BHQ1 and CBR/93:
Fam-TAG(+G)TTCAG(+C)GTTG(+A)(+C)(+T)GTG-
BHQ1. Reaction mixes were prepared using the qRT-
PCR one-step SuperScript III kit (Life Technologies) and
contained 12.5 μl 2? RT-PCR reaction mix, 0.5 μl Super-
script III/Taq polymerase enzyme mix, 600 nM of the 5?
primer and the 3? primer mix, 100 nM probe, 50 nM ROX
and 5 μl template RNA in a total reaction volume of 25 μl.
The thermocycling program used for the differential PCR
reactions was: 50?C for 30 min and 95?C for 2 min
followed by 45 cycles of 95?C for 15 s and 60?C for
1 min. In order to obtain RNA quantification standards,
RNA was extracted from stocks of each virus strain and
the concentration of total viral genomic RNA copies was
quantified using an in vitro transcribed RNA standard and
the CSFV-specific qRT-PCR [27]. These stocks were then
used to prepare ten-fold dilution series that allowed gener-
ation of standard curves specific for each strain and
quantification of the respective viral RNA copy num-
bers in each sample. Samples that had a Ct value
higher than the quantifiable detection limit of an
assay are indicated (<assay). The amount of 18S RNA
in the tonsil tissue extracts was quantified using a
QuantumRNA Universal 18S kit (Ambion) and was used
to normalize the viral copy number result according to
total RNA input. Viral copy number amounts in tonsil ho-
mogenates measured as log10 viral RNA copy number/ng
18S RNA were similarly classified as low if below 3.99,intermediate if between 4.00 and 5.99 and high if in excess
of 6.00.
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